Major Events - Silver诺医药-B (02591) is set to conduct an IPO from August 7 to August 12, with an expected listing date of August 15 [1] - Boan Biotech (06955) plans to place 48 million shares at a discount of approximately 8.78%, aiming to raise about HKD 780 million [1] - Derin Holdings (01709) intends to raise HKD 653.3 million, focusing on the development of blockchain, RWA, and virtual asset businesses [1] - Fuhong Hanlin (02696) received FDA approval to initiate a Phase 1 clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate for thymic cancer treatment [1] - China Biopharmaceutical (01177) obtained NMPA approval for the Phase II clinical trial application of LM-24C5, a dual antibody targeting CEACAM5/4-1BB [1] Financial Reports - China Mobile (00941) reported a shareholder profit of HKD 84.235 billion, a year-on-year increase of 5.03% [1] - Manulife Financial-S (00945) announced a core profit of CAD 1.7 billion for the second quarter [1] - Swire Properties (01972) reported a basic profit attributable to shareholders of HKD 4.42 billion, a year-on-year growth of 15% [1] - Hutchison Whampoa (00013) posted a net profit of USD 455 million, a significant year-on-year increase of 1663.32% [1] - MGM China (02282) disclosed a net profit of HKD 2.383 billion, a year-on-year decrease of 11.25% [1] - SMIC (00981) reported a shareholder profit of USD 132 million for the second quarter, with a revenue guidance for the third quarter indicating a sequential growth of 5% to 7% [1] - Zai Lab (09688) achieved a total revenue of approximately USD 216 million for the first half of the year, reflecting a year-on-year growth of 15.35% [1] - Innovent Biologics (01801) reported total product revenue exceeding RMB 5.2 billion for the first half of the year, maintaining a strong growth rate of over 35% [1] - Pacific Basin Shipping (02343) announced a profit attributable to shareholders of USD 25.6 million, a year-on-year decrease of 56% [1] - Lee & Man Paper Manufacturing (02314) reported a net profit of HKD 811 million, a year-on-year increase of 0.7%, with an interim dividend of HKD 0.066 per share [1] - Swire Group reported a profit attributable to shareholders of HKD 815 million for the first half of the year, a year-on-year decrease of 79% [1] - Lee & Man Chemical Company (00746) reported a profit increase of 36.0% to HKD 327 million, with an interim dividend of HKD 0.195 per share [1] - Hua Hong Semiconductor (01347) reported a profit attributable to parent company owners of USD 7.952 million for the second quarter, a year-on-year increase of 19.2% [1] - Wharf Real Estate Investment (01997) reported a loss attributable to shareholders of HKD 2.406 billion, a year-on-year increase of 128.71%, with the first interim dividend of HKD 0.066 per share [1] - Dekang Agriculture (02419) issued a profit warning, expecting a year-on-year increase in fair value adjustments of biological assets to approximately RMB 1.1 billion to 1.4 billion [1] - Mongol Mining (00975) issued a profit warning, anticipating a net loss of approximately USD 15 million to 25 million for the first half of the year, marking a shift from profit to loss [1] - Dongfeng Motor Group (00489) issued a profit warning, expecting a decline in net profit attributable to the parent company of 90% to 95% for the first half of the year [1]

Core Viewpoint - Dekang Agriculture (02419.HK) expects a significant increase in profit for the six months ending June 30, 2025, with projected earnings before fair value adjustments of biological assets between RMB 1,100 million and RMB 1,400 million, compared to RMB 363 million for the same period in 2024, driven by improved management efficiency and reduced costs of pig production [1]. Financial Performance - The projected profit for the upcoming period represents a substantial increase from the previous year's earnings, indicating a growth of approximately 203% to 286% [1]. - The increase in profitability is attributed to enhanced management effectiveness and economies of scale, alongside a continuous decline in pig production costs [1].

Core Viewpoint - Dekang Agriculture (02419) expects to achieve a profit before fair value adjustment of biological assets of approximately RMB 1.1 billion to RMB 1.4 billion for the six months ending June 30, 2025, compared to a profit of approximately RMB 363 million for the same period in 2024 [1] Group 1 - The expected increase in profit is primarily attributed to improved management efficiency and enhanced economies of scale [1] - The continuous decline in pig costs is also a significant factor contributing to the anticipated profit growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代碼：2419） 內幕消息 盈利預喜 本公告乃四川德康農牧食品集團股份有限公司（「本公司」，連同其附屬公司，「本集 團」）根據香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文及香港聯合 交易所有限公司證券上市規則（「《上市規則》」）第13.09條而作出。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東及潛在投資者，根據對本集 團截至2025年6月30日止六個月的未經審核綜合管理賬目及董事會現時所獲資料的 初步評估，本集團預期截至2025年6月30日止六個月將錄得生物資產公允價值調整 前利潤約人民幣1,100百萬元至人民幣1,400百萬元，而2024年同期錄得生物資產公 允價值調整前盈利約人民幣363百萬元。預期盈利上升主要歸因於公司管理效能、 規模化效應進一步提升，生豬成本持續下降。 本公司現正落實本集團截至2025年6月30日止六個月之中期業績公告。本公告所載 資料僅為董事會 ...

Core Viewpoint - The company, Dekang Agriculture (02419.HK), announced that it will hold a board meeting on August 15, 2025, to consider and approve its interim results for the six months ending June 30, 2025, and to discuss the potential declaration of an interim dividend, if applicable [1] Summary by Categories - **Company Announcement** - The board meeting is scheduled for August 15, 2025 [1] - The meeting will focus on the approval of interim results for the period ending June 30, 2025 [1] - The company will also consider the recommendation for an interim dividend [1]

四川德康農牧食品集團股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公 司將於二零二五年八月十五日（星期五）舉行董事會會議，藉以（其中包括）考慮及批 准本公司及其附屬公司截至二零二五年六月三十日止六個月的中期業績及其刊發， 並考慮建議派發中期股息（如有）。 承董事會命 四川德康農牧食品集團股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 DEKON FOOD AND AGRICULTURE GROUP 四川德康農牧食品集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代碼：2419） 董事會會議召開日期 董事長兼執行董事 王德根 香港，二零二五年八月五日 於本公告日期，本公司執行董事為王德根先生、王德輝先生、姚海龍先生、胡偉先 生及曾民先生；本公司非執行董事為劉珊女士；及本公司獨立非執行董事為潘鷹先 生、朱慶先生及馮志偉先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 四川德康農牧食品集團股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02419 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 157,588,454 | RMB | | 1 | RMB | | 157,588,454 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 157,588,454 | RMB | | 1 | RMB | | 157,58 ...

Group 1: Utilities - Recommended stock: Su Yan Jing Shen (603299.SH) due to its stable cash flow from traditional salt and salt chemical businesses, and the potential growth from gas storage projects [3][4] - The company is expected to enter a performance release period with the first phase of the gas storage project nearing production [4] Group 2: Pharmaceuticals - Recommended stock: Ang Li Kang (002940.SZ) as the impact of centralized procurement is gradually clearing, and new products are expected to drive revenue growth [4] - The introduction of ALK-N001, a promising anti-tumor candidate, is anticipated to enhance the company's innovation capabilities [4] Group 3: Media - Recommended stock: Alibaba-W (09988.HK) with a focus on the stabilization of traditional e-commerce and the potential for growth in the instant retail sector [5] - Alibaba Cloud's leading position in the domestic market and continuous revenue growth are highlighted [5] Group 4: Electronics - Recommended stock: Zhong Wei Company (688012.SH) due to its robust order backlog and continuous revenue growth driven by new product launches [6] Group 5: Non-Banking Financials - Recommended stock: China Life (601628.SH) for its excellent asset-liability matching and early transformation in dividend insurance sales [8] - The company is expected to release significant solvency capacity following asset reclassification [8] Group 6: Automotive - Recommended stock: Li Auto (02015.HK) as the company is positioned to leverage its strategic foresight and adaptability in the evolving automotive landscape [9] - The i-series is expected to maintain strong sales momentum, with the first model projected to achieve over 5,000 monthly sales [9] Group 7: Transportation - Recommended stock: YTO Express (600233.SH) with a leading growth rate in business volume, benefiting from the "anti-involution" trend in the industry [10] Group 8: Agriculture - Recommended stock: De Kang Agriculture (02419.HK) as it is positioned at a pivotal point in the agricultural sector, leveraging technology and innovative models for growth [12] - The company's platform strategy is expected to extend into other agricultural segments, enhancing its market presence [12] Group 9: Metals and New Materials - Recommended stock: Luoyang Molybdenum (603993.SH) with a strong performance in the first quarter, exceeding expectations [14] Group 10: North Exchange - Recommended stock: Yuan Hang Precision (833914.BJ) as a leading player in the domestic nickel-based conductor materials sector, benefiting from stable demand across multiple industries [14][15]

Key Points - The article highlights significant stock movements in the Hong Kong and US markets, with various companies experiencing notable gains and losses due to recent developments and announcements [1][2][3][4][5] Hong Kong Market Highlights - China Rare Earth Holdings (03788) surged nearly 20%, with a year-to-date increase of 320%, as the company proposed a spin-off of its gold segment for independent listing on the Hong Kong Stock Exchange [1] - Innovent Biologics (09969) rose nearly 4% after announcing the clinical approval of its new ADC innovative drug ICP-B794 [1] - North Sea Kangcheng - B (01228) increased over 50%, with its stock price doubling in three days, marking it as a rare disease stock in the Hong Kong market [1] - Hong Kong Travel (00308) saw a rise of over 24%, achieving a year-to-date stock price doubling, driven by market speculation on stablecoin cross-border payment scenarios [1] - CSPC Pharmaceutical Group (01093) gained nearly 3% after receiving drug registration approval for Mesalazine enteric-coated tablets, enhancing its product line in the immune system treatment sector [1] - Ruian Real Estate (00272) rose over 4%, with a cumulative contract property sales amount for the first six months increasing by 457% year-on-year [1] - Cornerstone Pharmaceuticals - B (02616) increased over 3%, planning to raise HKD 467 million for clinical research on CS2009 [1] - Q Technology (01478) rose over 7%, with mobile camera module sales of 32.648 million units in June, a year-on-year increase of 1.5% [1] - Dekang Agriculture and Animal Husbandry (02419) increased by 6%, with a new cycle logic continuing to strengthen, and Tianfeng Securities set a target price of HKD 154 [1] - Contemporary Amperex Technology (03750) rose over 3%, reaching a new high since its listing, following a deepened strategic cooperation agreement with Geely Automobile [2] - Gaming stocks continued to rise, with Wynn Macau (01128) up 6.49%, New World Development (00200) up 6.15%, and others showing similar gains [2] - Gold stocks faced declines, with Golden Resources (GORO.US) dropping nearly 10% and others following suit [4] US Market Highlights - Stablecoin concept stocks continued to rise, with Tiger Brokers (TIGR.US) increasing over 8% [4] - Trump Media & Technology Group (DJT.US) rose over 2% as the company seeks SEC approval for a blue-chip cryptocurrency ETF [4] - Wolfspeed (WOLF.US) continued to rise, with stock prices increasing over 9% [4] - Intel (INTC.US) rose over 7% after announcing company-wide layoffs [4] - JD.com (JD.US) increased over 2% as it launched its "Double Hundred Plan" for its delivery service [4]

Group 1 - The Hong Kong stock market has shown strong performance in the first half of the year, with the Hang Seng Index rising by 20%, making it one of the best performers globally [1] - The "Hong Kong Three Sisters"—Lao Pu Gold, Pop Mart, and Mixue Group—have gained significant attention, with Lao Pu Gold surging by 330%, Pop Mart by 200%, and Mixue Group by 96% [2][4] - A lesser-known player, Dekang Agriculture (02419), has also performed well, with its stock price increasing by 192% this year, peaking at a 247% rise [3] Group 2 - Dekang Agriculture's growth is driven by its low valuation and strong growth potential, primarily in pig farming, which constitutes about 80% of its business [5] - The company is projected to have a stable growth rate, with a 24% year-on-year increase in pig output expected in 2024, and ambitious targets of 31% and 30% growth for 2025 and 2026, respectively [6] - In comparison, major competitors like Muyuan Foods and Wens Foodstuffs are expected to have lower growth rates of 26% and 13%, respectively [6] Group 3 - Dekang Agriculture's cost structure is competitive, with a complete breeding cost of approximately 12.4 yuan/kg, placing it among the industry's top tier [8] - The company's debt-to-asset ratio is projected to be around 62.76% by the end of 2024, which is in line with the industry average, indicating manageable financial pressure [10] - The valuation method for pig farming companies is based on head average market value during the bottom of the pig cycle, with Dekang's head average market value at 2560 yuan, which is relatively low compared to peers [12] Group 4 - The current pig cycle is characterized by overproduction, with the national breeding sow inventory exceeding the target, leading to a downward pressure on pig prices [13] - The industry has seen improvements in breeding efficiency, with the average number of piglets weaned per sow increasing significantly, contributing to higher supply levels [13][14] - Despite the challenges, there is potential for policy interventions to stabilize the market, which could lead to temporary boosts in stock performance for companies like Dekang Agriculture [15]